After successfully launching a product in its lead indication, our client continued to explore additional oncology indications to expand the blockbuster franchise. Acsel was initially engaged to evaluate the market access landscape and evidence requirements in this follow-on indication, but after the initial delivery of findings, the client retained Acsel for a broader range of key access initiatives to support the launch.

Backed by thorough research, rigorous analysis, and extensive global experience, Acsel delivered a comprehensive portfolio of launch tools:

• PMA Landscape: an assessment of the evolving treatment landscape, pricing and access dynamics, payer perceptions on trial design and data scenarios, additional evidence requirements, and key strategic approaches
• Market Access Strategy: an overarching framework to synthesize strategic imperatives, access goals, and key drivers and barriers, along with value communication tools to ensure the speed and quality of access at launch
• Value Proposition: a compelling payer value story that provided clear rationale for supporting access
• Global Value Dossier: an evidentiary repository of materials and messages that conveyed the product’s payer value story to support national, regional, and local HTA, pricing and reimbursement submissions
• Objection Handler: key elements of the product’s value story and compelling, evidence-backed statements mapped to potential uncertainties and payer objections
• Ongoing Launch Support: a liaison between global value and access functions and key regions and markets
  

The Acsel team provided hands-on guidance through this journey and became an integral part of our client’s launch team. From the ongoing partnership, we understood the nuances of the product’s challenges across key markets, realized synergies, and delivered with precision to successfully go to market with an expanded breadth of indications.